Drug intelligence / Profile preview

FL761

Development stage: Preclinical
Lead developer: Canget BioTekpharma
Modality: Small Molecules
Administration: Oral

Overview

FL761 is a small molecule camptothecin analog developed by Canget BioTekpharma for the treatment of retinoblastoma. As an analog of FL118, it is designed to inhibit the expression of multiple anti-apoptotic proteins, including survivin (BIRC5), Mcl-1, XIAP, and cIAP2 (BIRC3), by suppressing their promoter activity. Unlike traditional camptothecins, FL118 and its analogs are reported to function independently of topoisomerase I inhibition. FL761 is currently in the preclinical stage, with in vitro studies demonstrating potential efficacy in retinoblastoma models.

Targets

XIAPBIRC5 (Survivin)MCL1 (Myeloid cell leukemia sequence 1)

Beyond the preview

Go deeper on FL761.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL761.

Explore the full profile